Regulation of Na+-coupled glucose carrier SGLT1 by human papillomavirus 18 E6 protein

Biochemical and Biophysical Research Communications

Volumn 404, Issue 2, 2011, Pages 695-700

  Leiprecht, Natalie ^a   Munoz, Carlos ^a   Alesutan, Ioana ^a   Siraskar, Gulab ^a   Sopjani, Mentor ^a   Föller, Michael ^a   Stubenrauch, Frank ^a   Iftner, Thomas ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cancer cells; E6 protein; Glucose transport; HPV

Indexed keywords

GLUCOSE; PROTEIN E6; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM ION;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CHEMOLUMINESCENCE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; GLUCOSE TRANSPORT; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; UPREGULATION; VOLTAGE CLAMP; WESTERN BLOTTING; XENOPUS;

ANIMALS; BREFELDIN A; CARCINOMA; CHEMILUMINESCENT MEASUREMENTS; DNA-BINDING PROTEINS; FEMALE; GLUCOSE; HELA CELLS; HUMAN PAPILLOMAVIRUS 18; HUMANS; MICROSCOPY, CONFOCAL; ONCOGENE PROTEINS, VIRAL; OOCYTES; SODIUM-GLUCOSE TRANSPORTER 1; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; XENOPUS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 18; PAPILLOMAVIRIDAE;

EID: 78651368840     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.12.044     Document Type: Article

References (40)

1. Nualart F., Los Angeles G.M., Medina R.A., Owen G.I. Glucose transporters in sex steroid hormone related cancer. Curr. Vasc. Pharmacol. 2009, 7:534-548.
2. Thorens B., Mueckler M. Glucose transporters in the 21st century. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E141-E145.
3. Wright E.M., Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004, 447:510-518.
4. Casneuf V.F., Fonteyne P., Van Damme N., Demetter P., Pauwels P., de Hemptinne B., De Vos M., Van de W.C., Peeters M. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest. 2008, 26:852-859.
5. Engelman J.A., Cantley L.C. A sweet new role for EGFR in cancer. Cancer Cell 2008, 13:375-376.
6. Ganapathy V., Thangaraju M., Prasad P.D. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 2009, 121:29-40.
7. Ishikawa N., Oguri T., Isobe T., Fujitaka K., Kohno N. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn. J. Cancer Res. 2001, 92:874-879.
8. Kidd M., Modlin I.M., Gustafsson B.I., Drozdov I., Hauso O., Pfragner R. Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295:G260-G272.
9. Macheda M.L., Rogers S., Best J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol. 2005, 202:654-662.
10. Matosin-Matekalo M., Mesonero J.E., Delezay O., Poiree J.C., Ilundain A.A., Brot-Laroche E. Thyroid hormone regulation of the Na+/glucose cotransporter SGLT1 in Caco-2 cells. Biochem. J. 1998, 334(Pt. 3):633-640.
11. Weihua Z., Tsan R., Huang W.C., Wu Q., Chiu C.H., Fidler I.J., Hung M.C. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008, 13:385-393.
12. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2:342-350.
13. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005, 6:204.
14. Parkin D.M., Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3). S3: 11-25.
15. Levine A.J. The common mechanisms of transformation by the small DNA tumor viruses: the inactivation of tumor suppressor gene products: p53. Virology 2009, 384:285-293.
16. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
17. Spanos W.C., Hoover A., Harris G.F., Wu S., Strand G.L., Anderson M.E., Klingelhutz A.J., Hendriks W., Bossler A.D., Lee J.H. The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J. Virol. 2008, 82:2493-2500.
18. Lee C., Laimins L.A. Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. J. Virol. 2004, 78:12366-12377.
19. Elbel M., Carl S., Spaderna S., Iftner T. A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential. Virology 1997, 239:132-149.
20. Foster S.A., Demers G.W., Etscheid B.G., Galloway D.A. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate Actinomycin D-induced growth arrest. J. Virol. 1994, 68:5698-5705.
21. James M.A., Lee J.H., Klingelhutz A.J. Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J. Virol. 2006, 80:5301-5307.
22. Kiyono T., Hiraiwa A., Fujita M., Hayashi Y., Akiyama T., Ishibashi M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. USA 1997, 94:11612-11616.
23. Muench P., Hiller T., Probst S., Florea A.M., Stubenrauch F., Iftner T. Binding of PDZ proteins to HPV E6 proteins does neither correlate with epidemiological risk classification nor with the immortalization of foreskin keratinocytes. Virology 2009, 387:380-387.
24. Nguyen M.L., Nguyen M.M., Lee D., Griep A.E., Lambert P.F. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J. Virol. 2003, 77:6957-6964.
25. Gardiol D., Kuhne C., Glaunsinger B., Lee S.S., Javier R., Banks L. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 1999, 18:5487-5496.
26. Glaunsinger B.A., Lee S.S., Thomas M., Banks L., Javier R. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 2000, 19:5270-5280.
27. Huibregtse J.M., Scheffner M., Howley P.M. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol. Cell. Biol. 1993, 13:775-784.
28. Lee S.S., Weiss R.S., Javier R.T. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. USA 1997, 94:6670-6675.
29. Nakagawa S., Huibregtse J.M. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell Biol. 2000, 20:8244-8253.
30. Dieter M., Palmada M., Rajamanickam J., Aydin A., Busjahn A., Boehmer C., Luft F.C., Lang F. Regulation of glucose transporter SGLT1 by ubiquitin ligase Nedd4-2 and kinases SGK1, SGK3, and PKB. Obes. Res. 2004, 12:862-870.
31. Broer S., Rahman B., Pellegri G., Pellerin L., Martin J.L., Verleysdonk S., Hamprecht B., Magistretti P.J. Comparison of lactate transport in astroglial cells and monocarboxylate transporter 1 (MCT 1) expressing Xenopus laevis oocytes. Expression of two different monocarboxylate transporters in astroglial cells and neurons. J. Biol. Chem. 1997, 272:30096-30102.
32. Stubenrauch F., Straub E., Fertey J., Iftner T. The E8 repression domain can replace the E2 transactivation domain for growth inhibition of HeLa cells by papillomavirus E2 proteins. Int. J. Cancer 2007, 121:2284-2292.
33. Boehmer C., Laufer J., Jeyaraj S., Klaus F., Lindner R., Lang F., Palmada M. Modulation of the voltage-gated potassium channel Kv1.5 by the SGK1 protein kinase involves inhibition of channel ubiquitination. Cell Physiol. Biochem. 2008, 22:591-600.
34. Sugawara Y., Eisbruch A., Kosuda S., Recker B.E., Kison P.V., Wahl R.L. Evaluation of FDG PET in patients with cervical cancer. J. Nucl. Med. 1999, 40:1125-1131.
35. Mendez L.E., Manci N., Cantuaria G., Gomez-Marin O., Penalver M., Braunschweiger P., Nadji M. Expression of glucose transporter-1 in cervical cancer and its precursors. Gynecol. Oncol. 2002, 86:138-143.
36. Rudlowski C., Becker A.J., Schroder W., Rath W., Buttner R., Moser M. GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am. J. Clin. Pathol. 2003, 120:691-698.
37. Hirsch J.R., Loo D.D., Wright E.M. Regulation of Na+/glucose cotransporter expression by protein kinases in Xenopus laevis oocytes. J. Biol. Chem. 1996, 271:14740-14746.
38. Subramanian S., Glitz P., Kipp H., Kinne R.K., Castaneda F. Protein kinase-A affects sorting and conformation of the sodium-dependent glucose co-transporter SGLT1. J. Cell Biochem. 2009, 106:444-452.
39. Sopjani M., Bhavsar S.K., Fraser S., Kemp B.E., Foller M., Lang F. Regulation of Na+-coupled glucose carrier SGLT1 by AMP-activated protein kinase. Mol. Membr. Biol. 2010, 27:137-144.
40. Lang F., Busch G.L., Ritter M., Volkl H., Waldegger S., Gulbins E., Haussinger D. Functional significance of cell volume regulatory mechanisms. Physiol. Rev. 1998, 78:247-306.